Rallybio Corp (RLYB) income statement
RLYBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 10/30
$15.52+0.26 (+1.70%)
Close on Nov 19, 2026Market cap $83.56MP/E 3.4Yield –
Rallybio Corp income statement
Ratios
Latest available, balances at Sep 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -5580.9%
- Net margin
- 6177.4%
- Return on equity, FY2025
- -15.0%
Financial strength
- Current ratio
- 28.87
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 2762.5%
Valuation
- P/E ratio
- 3.4
- Price to sales
- 192.53
- Price to book
- 0.91
- Dividend yield
- –
See a number that looks wrong?